Novartis Faces Questions About Safety Of COPD Treatment | Markets | Minyanville.com
Links shared publicly online about this topic.
- 462total visits
Novartis Faces Questions About Safety Of COPD Treatment | Markets | Minyanville.com
The company hopes to win approval for two dosing levels of inhaler for chronic disease. Safety concerns may trip up the panel of government advisers next week.
View full resource at minyanville.com
Tags: COPD, COPD Medication, FDA, Novartis, disease, Safety, Medical
Most Recently Shared on March 5, 2011 at 6:28 am By:
Novartis prepares for FDA meet on new #COPD medicine, Arcapta http://t.co/CM92ybG
Advertisement
